Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20039 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Hongbin Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Ritonavir, Hematologic Neoplasms, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This research was supported by National Natural Science Foundation (No. 82370171) and Natural Science Foundation of Sichuan Province (No. 2025ZNSFSC0989)..
Abstract (Originalsprache)
Patients with haematological malignancies (HMs) are highly vulnerable to COVID‐19 due to their immunocompromised status, which leads to prolonged viral clearance and severe outcomes. Nirmatrelvir/ritonavir has shown efficacy in reducing severity and mortality in high‐risk COVID‐19 outpatients, but its effectiveness in hospitalized HM patients remains unclear. We conducted a retrospective study to assess the effectiveness of nirmatrelvir/ritonavir on mortality and viral clearance in hospitalized HM patients with mild‐to‐moderate COVID‐19 during China's first COVID‐19 surge. Mortality rate and viral clearance time were the primary end‐points. Cox proportional hazards models were used to detect factors associated with mortality and viral clearance. A total of 116 HM patients, with a median age of 47.2 years, hospitalized for a minimum of 5 days with mild‐to‐moderate COVID‐19, were included in this study. There was no difference in the 90‐day mortality rate between HM patients treated with nirmatrelvir/ritonavir within 5 days and those not treated (4.9% vs. 5.3%, p = 1.000). Nirmatrelvir/ritonavir use within 5 days reduced the time to viral clearance (hazard ratio [HR] = 1.59, 95% confidence interval [CI] 1.04–2.42). Nirmatrelvir/ritonavir use within 5 days in hospitalized HM patients with mild‐to‐moderate COVID‐19 does not reduce mortality but accelerates viral clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
- West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Förderung
- This research was supported by National Natural Science Foundation (No. 82370171) and Natural Science Foundation of Sichuan Province (No. 2025ZNSFSC0989).
Zitieren
APA
Yu, H., Chen, T., Li, J., Zhang, X., & Wu, Y. (2025). Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study. British Journal of Haematology. https://doi.org/10.1111/bjh.20039
Vancouver
Yu H, Chen T, Li J, Zhang X, Wu Y. Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study. British Journal of Haematology. 2025. doi:10.1111/bjh.20039
BibTeX
@article{Yu2025,
author = {Yu, Hongbin and Chen, Tian and Li, Jiawei and Zhang, Xin and Wu, Yu},
title = {Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20039}
}
EUVIMED